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Summary.-The sera of80 newly diagnosed lung-cancer patients have been examined
for immune complexes and autoantibodies. Control subjects consisted of20 bronchitic
patients and 150 normal blood donors. Immune-complex measurements used 4
established and sensitive techniques (Raji cell assay, fluid and solid-phase Clq assays
and conglutinin-binding assay) and a 5th newly devised technique based on the
binding of polyethylene-glycol-precipitated immune-complex-rich serum fractions
to Staphylococcus aureus. Using the Raji cell assay and the S. aureus binding assay
to measure immune complexes, both newly diagnosed lung cancer patients and bron-
chitic patients had significantly higher prevalences of immune complexes than
normal controls, but the two groups of patients did not differ significantlv in either
prevalence or quantity of immune complexes. When techniques which depend
solely upon complement fixation (Clq assays and conglutinin binding) were used,
only meagre quantities of immune complexes were found, and in at most 15% of
newly diagnosed lung-cancer patients. The presence of autoantibodies in newly
diagnosed cancer patients and controls appeared to correlate with the increase in the
detectable prevalence of immune complexes.
THE PRESENCE of circulating immune
complexes in a variety of human dis-
orders, notably the idiopathic inflam-
matory diseases such as systemic lupus
erythematosus and rheumatoid arthritis,
is now well established. In some human
malignant diseases, agents of the kind
originally described as "blocking factors"
by the Hellstroms more than a decade ago
(Hellstrom et al., 1969) have since been
recognized as complexes of antigens and
antibodies (Sjogren et al., 1971; Hellstrom
et al., 1977). With the advent of better
techniques for their detection, apparently
successful efforts have been made to find
immune complexes in various human
malignancies (Theofilopoulos et al., 1977;
Lambert et al., 1978; Baldwin et al., 1979).
However, since the existing assays for
immune complexes are antigenically non-
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specific, it may be expected that not all
the immune complexes so far detected in
malignant disease will be found to contain
tumour-related antigens.
In this paper are described studies of
immune complexes in the sera of a large
group of patients with lung cancer, ex-
amined near to the time of clinical pre-
sentation of the disease and before the
start of treatment. Of the 18 methods
subjected to a recent international study
(Lambert et al., 1978) 4 of the more sensi-
tive (the Raji cell radioimmunoassay, the
fluid phase and solid phase Clq assays and
the conglutinin-binding test) have been
used to detect immune complexes. In
addition, a newly devised technique based
on the binding of immune complexes to
Staphylococcus aureus has been used.
The significance attached to immune
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complexes in cancer relates to the con-
cepts, expressed in earlier studies (Hells-
trom et al., 1969; Sjogren et al., 1971) that
immune complexes may have unfavour-
able influences upon the immunity of
tumour-bearing hosts. The implication of
these concepts is that such complexes
may comprise anti-tumour antibodies and
tumour-cell antigens.
MATERIALS AND METHODS
Subjects
Sera were obtained from 80 lung-cancer
patients at the City Hospital, Edinburgh. All
were studied before the start oftreatment and
only those patients with a subsequently con-
firmed diagnosis of bronchogenic carcinoma
were included. Normal control sera were
obtained from 150 randomly selected blood
donors. Sera were also obtained from 20
bronchitic patients to serve as benign chest-
disease controls of comparable age to the
cancer patients, and from patients with
either rheumatoid arthritis or insulin-depend-
ent diabetes to serve as positive controls for
immune-complex assays. Sera were collected
only from bronchitic patients clinically
judged not to be suffering from infection at
that time. Sera were stored in aliquots at
-40°C. The age range of the lung-cancer
patients was 47-84 years, of the bronchitic
patients 50-82 years, and ofthe normal blood
donors 18-58 years.
Immunological reagents
Protein A (Pharmacia) was radiolabelled to
a sp. act. of20 /tCi/,ug by an adaptation ofthe
chloramine-T method (Dorval et al., 1975).
Human Clq was purified by the method of
Yonemasu & Stroud (1971) and radiolabelled
to a sp. act. of 1 ,Ci/,ug, using lactoperoxidase
(Heusser et al., 1973). Bovine conglutinin was
purified by absorption to yeast (Lachmann,
1967) and further purified by DEAE-A50
chromatography. Standard preparations of
aggregated Ig were tested whenever immune-
complex assays were performed. Cohn Frac-
tion II Ig was ultracentrifuged at 100,000 g
and aggregated by heating at 63°C for 20 min.
Standard preparations were made by diluting
aggregated Ig from 1 mg/ml in serial doubling
dilutions in normal human serum to 1-2
'4g/ml.
Immune-complex assays
Raji cell radioimmunoassay (RAJI).-Cells
of the lymphoblastoid line Raji were cul-
tured in RPMI-1640 containing 10% foetal
calf serum, 10% tryptose-phosphate broth,
antibiotic antimycotic solution and 3-(N-
morpholino) propane-sulphonic acid. Viability
of the harvested cells was routinely 90-95%.
The assay was performed according to the
method of Theofilopoulos et al. (1976), except
that 1251-protein A (12.5 ng; 2-5 x 105 ct/min)
was used instead of anti-IgG to detect Raji
cell-bound immune complexes. Results were
expressed as ,ug of aggregated Ig equivalents
per ml ofundiluted serum, by reference to the
uptake ofstandard preparations ofaggregated
Ig in normal human serum. The minimum
amount of aggregated Ig equivalents readily
and routinely detectable corresponded to
20 jug/ml, so 21 ,ug/ml was taken as the lower
limit of positivity. This modification of
RAJI has been used successfully in other
studies (Irvine et al., 1978a).
Solid-phase Clq assay (Clq-SP).-The tech-
nique of Svehag (1975) adapted by Hay et al.
(1977) was used with 1251-protein A (2-5 ng;
5x 104 ct/min). Results were expressed as
percentage Protein A bound, and those re-
sults exceeding the 90th percentile of normal
blood-donor control values were considered
positive.
Fluid-phase Clq assay (Clq-FP). The test
described by Zubler et al. (1976) with EDTA
treatment of sera was used without modifica-
tion. Those percentage Clq-binding values
found to exceed the mean+2 s.d. ofthe mean
ofnormal controls were considered positive.
Conglutinin- binding test (Kg-B).-The
assay described by Casali et al. (1977) was
used with 1251-protein A (5 ng; 105 ct/min).
Results were expressed as ,g/ml of aggre-
gated Ig equivalents, by reference to standard
preparations of aggregated Ig. Those results
which exceeded the 90th percentile of normal
control subjects were considered positive.
Staphylococcus aureus binding test (STAB).
-This is a newly devised assay, details of
which are to be reported elsewhere (Barkas,
1980). Briefly, 100 ,u of each serum was
treated with EDTA and 2 ml of 6% poly-
ethylene glycol 6000 (PEG) in borate-saline
buffer (pH 8.4) was added. After overnight
incubation at 4°C, precipitates were recovered
by centrifugation, washed in 5% PEG and
redissolved in phosphate-buffered saline
(PBS) pH 7-2. To duplicate lOO,ul aliquots of
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resuspended material was added 100 jul of a
1% suspension of heat-killed and formalin-
fixed S. aureus suspension in PBS plus 0.5%
bovine serum albumin. After incubation at
37°C for 1 h the staphylococci were washed
twice and 30 ng of 1251-Protein A was added
to each tube. After 30min incubation at 4°C
the staphyloccoci were washed twice and the
amounts of 1251-Protein A bound were-deter-
mined. Results were expressed as percent
Protein A bound and results above the mean
+2 s.d. of normal controls were considered
positive.
Autoantibodies.-Standard immunofluores-
cence techniques with anti-human IgG and
sections of rat tissues were used, except for
thyroid autoantibodies, when human thyroid
sections were used. Conventional tanned-red-
cell tests with thyroglobulin and thyroid
microsomal antigens were also used. All tests
for autoantibodies were performed by indi-
viduals without knowledge of the identity of
the sera or of the results of immune-complex
assays.
RESULTS
Immune-complex measurements in newly
diagnosed lung-cancer patients and controls
Initially, sera from newly diagnosed
patients were tested by RAJI and Clq
techniques. Different immune-complex
assays preferentially detect subspecies of
immune complexes which are defined by
characteristics of the complex such as Ig
class and subclass, antigen valency, com-
plex size and the ability of the complex to
activate the complement system (WHO
Technical Report Series, 1977). The paral-
lel use of two or more immune complex
assays may help to avdid such method-
ological restrictions.
Raji cell radioimmunoassay.-Consider-
able overlap among the values obtained
for patients and controls was apparent in
the results, but 18/41 sera from lung-
cancer patients (44%, P<0*05, Fisher's
test) and 50% of 16 sera from bronchitic
patients (P< 0-05) gave values above 20
,ug/ml in comparison with 23-5% (16) of
68 normal blood donors (Fig. 1). There
were no significant differences between
the values for positive lung cancer and
bronchitis sera (Mann-Whitney test) or
between the prevalences of immune com-
plexes in these patients (Fisher's test).
Fluid-phase Clq binding.-Of 80 lung-
cancer sera, 12 gave Clq binding above
normal control levels (15%, P < 0-05 from
x2) and 1 of 18 bronchitis sera waspositive
(6%, not significant) (Fig. 2). Of 10
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FIG. 1.-Immune complexes detected by
RAJI in the sera of lung-cancer patients
and controls. Horizontal line drawn at
20 ,ug/ml represents the limit of positivity.
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FIG. 2.-Immune complexes detected by
Clq-FP in the sera of lung-cancer patients
and controls. Horizontal line represents
the mean + 2 s.d. ofthe blood-donor control.
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rheutmatoid-arthritis sera included as posi-
tive controls, 9 were positive. Ofthe cancer
and bronchitis sera 35 and 15 respectively
were also tested by RAJI. The concord-
ance between RAJI and Clq-FP was 570o
in cancer and 60% in bronchitis.
Solid-phase Clq binding. There were no
significant differences among the pre-
valences of immune complexes detected
in lung cancer (1 30o), bronchitis (6%) or in
the sera of 80 normal blood donors (10%).
Of 54 cancer sera tested by Clq-SP, 51
were also tested by Clq-FP, and 84% of
the results were in agreement. The results
were totally in accord for 15 bronchitis
sera tested in both assays. Of the 10
rheumatoid-arthritis sera tested also by
Clq-FP, 5 were positive. These results for
rheumatoid arthritis agree with results of
more extensive studies (Lambert et al.,
1978) and indicate that, ofthe Clq binding
tests, the fluid-phase test is more sensitive
than the solid-phase test in rheumatoid
arthritis.
Because of the apparently different
prevalences of immune complexes de-
tectable in lung-cancer sera by RAJI and
Clq binding tests, confirmation of the
prevalence of complement-binding im-
mune complexes was sought in the con-
glutinin-binding (Kg-B) test. The bovine
protein conglutinin has a high affinity for
C3bi. The characteristics of artificially
formed immune complexes which facilitate
their detection by RAJI and Kg-B appear
to be similar (Casali et al., 1977).
Conglutinin binding test. There was no
evidence of conglutinin-binding iinmune
complexes in sera from newly diagnosed
lung-cancer patients. Only 3/75 tested
gave any detectable Kg-B values and these
(5-10 ,ug/ml) fell below the 90th percentile
(17 ,ug/ml) ofthe normal control group. Of
103 normal blood donor sera tested, about
100% gave clearly positive values and these
sera were also positive by RAJI. Of 14 sera
from insulin-treated diabetics included as
positive controls, 12 gave Kg-B binding
between 3 and 215 ,ug/ml and 5 of these
sera fell above the 90th percentile of
normal control values (P<0.02, x2 test).
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Fis'. 3. Immune complexes detected by
Staphylococcus aureus bindinlg in the sera
of lung-cancer patients and(l cointrols.
Horizontal line represents the mean
+2 s.d. of the blood-donor control group.
We have previously shown by Clq binding
that the prevalence of immune complexes
in insulin-treated diabetics is of this order
(Irvine et al., 1978b). The addition of
normal human serum, as a complement
source, to cancer sera did not produce any
increase in Kg-B binding.
Staphylococcus aureus binding test. Of
42 sera from newly diagnosed lung-cancer
patients, 14 (330o, P < 0-05 Fisher's test)
gave values above the mean + 2 s.d. of
normal controls (Fig. 3). Similarly, of 18
bronchitic sera tested 8 were positive
(440o, P < 0.02). There was no significant
difference between the prevalence of com-
plexes in cancer and bronchitis. The con-
cordance rate for tests on patients' sera
between RAJI and STAB was 540 and
between Clq-FP and STAB was 7000.
The relationship of autoantibodies to the
detection of immune comnplexes
A variety of autoantibodies were found
in the sera of lung-cancer and bronchitic
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TABLE. Prevalence of autoantibodies in the sera of lung-cancer patients and controls
Autoantibody
nt ti
:39
16
49
1 2
6
12
Specificity
SNA GLOM THY GPC ANF RET BM
:1 2 4 4 1 0 0
1 0 2 0 3 0 0
2 4 4 0 1 1
* Selected to ilelu(le a number of RAJI-positive sera: SMA=Smootlh-muscle antibody; GLOMNI=renal
glomerulus; ANF =antinuclear factor; BI = baseement membrane; THY = thyroid; GPC =gastric parietal
(ell; RET=reticulin (RS type).
50
0
0.30
0
z
LUNG BRONCHITIS NORMAL COMBINED
CANCER DATA
NO: 39 16 40 95
Vit(J 4. The prevalence of immuine om-
plexes dletecte(t by RAJI in thle .sera of
lutnig-cancer patients andl controls accor(ling
to the presence (*) or absence (O) of
(letectable autoantibodies in the sera. Only
for the combinecd (lata is 'the (lifference
between autoantibody negative an(l posi-
tive statistically significant (P < 0-025).
patients, and also in the sera of blood-
donor controls (Table). The latter group
was selected to include a number ofRAJI-
positive sera. When the prevalence of
immune complexes detectable by RAJI
was compared with the presence of auto-
antibodies in the sera, similar trends
emerged for all 3 groups of subjects. The
sera of subjects found positive for auto-
antibodies had considerably higher pre-
valences of immune complexes than those
found negative for autoantibodies (Fig. 4).
The association was not statistically sig-
nificant for any single group of subjects,
but when all the results were considered
together, statistical significance was
attained (P < 0-025, x2 test). There was no
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Autoantibody Autoantibody
Negative Positive
No. 27 15
Fie". 5.-Quantities of irnmunie complexes
found in the sera oflung-canicer patients by
S. aureus binding according to the presence
or absence of (detectable autoantibolies in
the sera. Horizontal bar as in Fig. 3.
(P< 0.05)
apparent relationship between immune
complexes detectable by Clq-FP and auto-
antibodies. However, a similar positive
trend was found when the values for
immune complexes detectable byS. aureus
binding in lung cancer were considered
(Fig. 5). Those sera found positive for auto-
antibodies had significantly higher staphy-
lococcal-binding (P < 0.05, Mann-Whitney
test) than autoantibody-negative sera.
Correlation of immune complexes with
tumourpathology
There were no detectable correlations
among immiune-complex results and size,
Group
LuIIng cancer
BHIonchtitis
Normal*
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spread or histological types ofthe tumours
(data not shown).
D)ISCUSS1ON
Of the vast number of techniques (le-
vised for the detection of immune com-
plexes, 4 assays considered to be among
the more sensitive (Lambert et at., 1978),
and a further recently devised assay, have
been used to examine the sera of patients
with lung cancer. It is considered to be an
important aspect of the study that sera
were collected from a group of patients at
about the time the disease became clinic-
ally apparent and before the start of
treatment.
Using techniques whiclh exploit com-
plement-binding alone to measure immune
complexes (Clq-SP, Clq-FP and Kg-B)
15% at most of lung-cancer patients
appeared to have measurable levels of
complexes. With two further assays
(RAJI and STAB) which appear to detect
both complement-binding and non-com-
plement-binding immune complexes (Guy
& Di Mario, unpublished results; Barkas,
1981) higher prevalences of complexes
were found in cancer patients. Immune-
complex-induced glomerulonephritis may
arise in lung cancer (Loughridge & Lewis,
1971) but it appears to be rare. This may
indicate that pathologically harmful im-
mune complexes are infrequent in lung
cancer, or that conditions which may
favour the deposition of complexes and
subsequent tissue damage (i.e. comple-
ment fixation and subsequent comple-
ment-mediated inflammatory responses)
do not pertain.
Immune complexes were also found in
patients with benign chest disease at
prevalences not dissimilar from those for
lung cancer. In both bronchitic and lung-
cancer patients, infection may contribute
to the formation of serum immune com-
plexes, though bronchitic patients with
clinical infection at the time ofstudy were
excluded. In all subjects, including nor-
mals, the increase in autoimmune pheno-
mena which accompanies ageing (Irvine
et al., 1970; Burnet, 1974) may perhaps
lead to an increased formation of immune
complexes comprising autoantigens. This
is supported here by the correlation be-
tween serunm autoantibodies and immune
complexes. Elsewhere we have shown that
the prevalences of immune complexes
detectable by Raji and Kg-B assays in
the sera of normal subjects show increases
with advancing age of the subjects (Di
Mario et al., 1981). However, there are
some lung-cancer patients who have
immune complexes which do not appear to
be attributable to autoantibodies, and it
remains to be seen whether they contain
tumour antigens.
A number of studies of immune com-
plexes in lung cancer have been reported.
Some have examined patients responding
to treatment, and this makes it difficult to
make any comparison with the untreated
patients who formed the major part of the
present study. For instance, ofthe 24lung-
cancer patients studied by Rossen et al.
(1977) by a Clq-binding technique, 88%
had evidence of immune complexes, but
all had had surgical therapy for their
disease and were highly selected to include
patients likely to develop recurrent neo-
plastic growth. Using RAJI, Theofil-
opoulos et al. (1977) found immune com-
plexes in only 26% oflung-cancer patients
in comparison with 19% of normal con-
trols. Barkas et al. (1976) did not find
significant levels of complexes in lung-
cancer patients, using antibody-dependent
cell-mediated cytotoxicity. Complement
and immunoglobulin inclusions, as evi-
dence of phagocytosed immune complexes,
were found in the polymorphonuclear
leucocytes of most of the lung-cancer
patients studied by Jansen et al. (1977).
A surprising aspect of this and other
studies (Schrohenloher et al., 1.978) is the
apparent lack of correlation among the
results of immune-complex assays used in
investigations of lung-cancer patients. In
studies of immune complexes in other
diseases, satisfactory correlations between
assays have been shown (Lambert et al.,
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1978; Irvine et al., 1978b). The reasons for
such disparity no doubt involve differ-
ences in methodology, but may also reflect
possible heterogeneity of immune com-
plexes in lung cancer. Such possible
heterogeneity complicates the interpre-
tation of immune-complex results from
existing assay procedures, and clearly
necessitates the development of tumour-
antigen-specific methods.
There is no clear evidence yet that
immune complexes in lung cancer contain
unique tumour antigens, though recur-
rence oftumour growth and immune com-
plexes appear to correlate in the studies of
Rossen et al. (1977). Surgical removal of
tumour is associated with a reduction in
polymorphonuclear leucocyte inclusions
(Jansen et al., 1977), implying a decline in
immune-complex levels. However, these
results do not necessarily imply tumour
specificity of the immune complexes, in
view ofthe diversity in immune complexes
found by different techniques and their
association with autoantibodies. In pre-
liminary experiments (Guy & James, un-
published) using gel-filtration chromato-
graphy and polyacrylamide-gel electro-
phoresis, we have been unable to find
components of immune complexes which
are unique to the sera of lung-cancer
patients.
A fundamental problem, relevant to
tumour immunology in general and to
lung cancer in particular, is the possible
biological significance of tumour antigens.
Thus, although a number of onco-foetal
antigens have been found to be associated
with lung cancer (Lo Gerfo, 1976) their
specificity and immunogenicity remain in
doubt. The specificity of antigens found in
immune complexes in the sera of lung-
cancer patients is therefore of obvious
importance and as yet unresolved.
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